Because testing for PTH, phosphorus, and 25D likely is primarily undertaken by nephrologists, at least for stage 4 and 5 patients, this suggests that nephrologists may not be following the KDIGO guideline3 as much as would be desirable, potentially suggesting missed opportunities for CKD-MBD treatment. This evidence concerns the gene PTH and Marchiafava-Bignami disease.